Clinical Trials Browser

Recruiting × Dexamethasone × Gastrointestinal × Clear all

Colonic Neoplasms, Colorectal Neoplasms

NCT05319730 2026-03-02

MK-3475-06B

Phase 1/2 Recruiting

230 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05286814 2026-02-24

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Phase 2 Recruiting

70 enrolled

EndocrineGastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Bile Duct Neoplasms, Colorectal Neoplasms, Adrenocortical Carcinoma, Cholangiocarcinoma

NCT04891289 2025-11-24

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Phase 2 Recruiting

164 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05727163 2025-05-30

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Phase 2 Recruiting

194 enrolled

Gastrointestinal

Colorectal Cancer Metastatic

Clinical Trials

PILDI

MK-3475-06B

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients